Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 3/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | GRM4 | Q14833 | 3/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.32 |
| ▸ | APBA1 | Q02410 | 1/20 | 0.32 |
| ▸ | MPO | P05164 | 1/20 | 0.30 |
| ▸ | ATM | Q13315 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL126770 | 0.82 | NPC1 (0.39) | — | |
| SCHEMBL128601 | 0.81 | CYP2D6 (0.41) | — | |
| SCHEMBL23674743 | 0.79 | LTA4H (0.37) | TSHR | |
| SCHEMBL2067243 | 0.78 | ALDH1A1 (0.38) | — | |
| SCHEMBL29108987 | 0.78 | — | — | |
| SCHEMBL2478733 | 0.78 | CHRNB2 (0.44) | — | |
| SCHEMBL128768 | 0.78 | — | — | |
| SCHEMBL126131 | 0.77 | — | — | |
| SCHEMBL2067748 | 0.77 | PDE5A (0.33) | — | |
| SCHEMBL2067626 | 0.77 | LSS (0.40) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4373825-A1 | NITRILE SUMO INHIBITORS AND USES THEREOF | Suvalent Therapeutics, Inc. (US) | 2024-05-29 | — | — | EP | claimed |
| US-20230303584-A1 | 4,5,6,7-TETRAHYDROTHIENO[2,3-C]PYRIDINE SUMO INHIBITORS AND USES THEREOF | CIT THERAPEUTICS LLC | 2023-09-28 | — | — | US | claimed |
| WO-2023004376-A1 | NITRILE SUMO INHIBITORS AND USES THEREOF | Suvalent Therapeutics, Inc. (US) | 2023-01-26 | — | — | WO | claimed |
| WO-2021150918-A1 | 4,5,6,7-TETRAHYDROTHIENO[2,3-C]PYRIDINE SUMO INHIBITORS AND USES THEREOF | ONCOVALENT THERAPEUTICS INC. (US) | 2021-07-29 | — | — | WO | claimed |
| EP-4373825-A1 | NITRILE SUMO INHIBITORS AND USES THEREOF | Suvalent Therapeutics, Inc. (US) | 2024-05-29 | — | — | EP | disclosed |
| WO-2024086194-A1 | COMBINATION THERAPY FOR TREATMENT OF CANCER | Suvalent Therapeutics, Inc. (US) | 2024-04-25 | — | — | WO | disclosed |
| US-20230303584-A1 | 4,5,6,7-TETRAHYDROTHIENO[2,3-C]PYRIDINE SUMO INHIBITORS AND USES THEREOF | CIT THERAPEUTICS LLC | 2023-09-28 | — | — | US | disclosed |
| WO-2023004376-A1 | NITRILE SUMO INHIBITORS AND USES THEREOF | Suvalent Therapeutics, Inc. (US) | 2023-01-26 | — | — | WO | disclosed |
| CN-114773249-A | Compounds, pharmaceutical compositions and methods for treating inflammatory diseases | 艾匹克治疗公司 | 2022-07-22 | — | — | CN | disclosed |
| WO-2021150918-A1 | 4,5,6,7-TETRAHYDROTHIENO[2,3-C]PYRIDINE SUMO INHIBITORS AND USES THEREOF | ONCOVALENT THERAPEUTICS INC. (US) | 2021-07-29 | — | — | WO | disclosed |
| US-11072582-B2 | Substituted pyrrolidines as G-protein coupled receptor 43 agonists | EPICS THERAPEUTICS (BE) | 2021-07-27 | — | — | US | disclosed |
| US-20200347016-A1 | SUBSTITUTED PYRROLIDINES AS G-PROTEIN COUPLED RECEPTOR 43 AGONISTS | EPICS THERAPEUTICS (BE) | 2020-11-05 | — | — | US | disclosed |
| US-20100317652-A1 | Compounds Useful In Therapy | PFIZER INC | 2010-12-16 | — | — | US | disclosed |
| US-20100317657-A1 | 1H-IMIDAZO[4,5-c]QUINOLINONE DERIVATIVES | NOVARTIS AG | 2010-12-16 | — | — | US | disclosed |
| WO-2010139731-A1 | 1H-IMIDAZO[4,5-c]QUINOLINONE DERIVATIVES | NOVARTIS AG (CH) | 2010-12-09 | — | — | WO | disclosed |
| WO-2010139747-A1 | 1H-IMIDAZO[4, 5-c]QUINOLINONE COMPOUNDS, USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES | NOVARTIS AG (CH) | 2010-12-09 | — | — | WO | disclosed |
| US-20100311714-A1 | 1H-IMIDAZO[4,5-c]QUINOLINONE COMPOUNDS | NOVARTIS AG (CH) | 2010-12-09 | — | — | US | disclosed |
| US-7745630-B2 | Triazolyl piperidine arginine vasopressin receptor modulators | BRYANS JUSTIN STEPHEN | 2010-06-29 | — | — | US | disclosed |
| US-20050154024-A1 | Compounds useful in therapy | PFIZER INC | 2005-07-14 | — | — | US | disclosed |
| US-20030134880-A1 | Novel cd23 inhibitors | SMITHKLINE BEECHAM P.L.C. (GB) | 2003-07-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100311714-A1 | 1H-IMIDAZO[4,5-c]QUINOLINONE COMPOUNDS | PRKCA, ABL1, MYLK2 | KDM1A 1234/4885TSHR 3303/4885GRM4 2203/4885 |
| US-20200347016-A1 | SUBSTITUTED PYRROLIDINES AS G-PROTEIN COUPLED RECEPTOR 43 AGONISTS | GPR119, GPR52, GPR88 | KDM1A 4422/4885TSHR 257/4885GRM4 161/4885 |
| US-20230303584-A1 | 4,5,6,7-TETRAHYDROTHIENO[2,3-C]PYRIDINE SUMO INHIBITORS AND USES THEREOF | SUMO1, SUMO3, SUMO2 | KDM1A 285/4885TSHR 4336/4885GRM4 4099/4885 |
| US-20030134880-A1 | Novel cd23 inhibitors | CD2, CD22, CD40 | KDM1A 3235/4885TSHR 544/4885GRM4 2772/4885 |
| US-11072582-B2 | Substituted pyrrolidines as G-protein coupled receptor 43 agonists | GPR119, GPR52, GPR88 | KDM1A 4422/4885TSHR 257/4885GRM4 161/4885 |
| US-20050154024-A1 | Compounds useful in therapy | PTGER4, PTGER3, ALOX5 | KDM1A 4400/4885TSHR 577/4885GRM4 565/4885 |
| US-20100317652-A1 | Compounds Useful In Therapy | AVPR1A, AVPR1B, AVPR2 | KDM1A 1329/4885TSHR 1559/4885GRM4 754/4885 |
| US-20100317657-A1 | 1H-IMIDAZO[4,5-c]QUINOLINONE DERIVATIVES | PRKCA, CSNK1A1, ABL1 | KDM1A 1261/4885TSHR 3111/4885GRM4 2302/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.